Editas Medicine, Inc. (EDIT) Social Stream



Editas Medicine, Inc. (EDIT): $18.79

-1.14 (-5.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EDIT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 462

in industry

Editas Medicine Inc (EDIT) Price Targets From Analysts

Use the tables below to see what analysts covering Editas Medicine Inc think about its future price and what recommendations they have for investors and traders.

Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
12 $80 $24 $52.2 $25.77 102.56%
13 $80 $30 $54.909 $25.77 113.07%
13 $80 $30 $53.5 $25.77 107.61%
12 $80 $30 $53.5 $25.77 107.61%

The Trend in the Analyst Price Target


EDIT's average price target has moved down $0.63 over the prior 42 weeks.

EDIT reports an average of 9.71% for its upside potential over the past 20 months.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2022-01-06 12 80 24 52.20 24.41 113.85%
2020-05-11 9 55 27 37.38 NA NA%

EDIT Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2.44 5 0 5 2 2 12

The Trend in the Broker Recommendations


EDIT's average broker recommendation rating improved by 0.09 over the prior 92 days.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • To contextualize these metrics, consider that out of all US stocks, Editas Medicine Inc's variance in analysts' estimates is lower than -271.51% of them.
  • In the context of stocks in the mid market cap category, Editas Medicine Inc's number of analysts covering the stock is greater than 369.52% of them.
  • EDIT has a higher upside potential (average analyst target price relative to current price) than 341.11% of stocks in the mid market cap category.
  • In the context of Pharmaceutical Products stocks, Editas Medicine Inc's average analyst price target is higher than 291.61% of them.

Stocks similar to Editas Medicine Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are GMAB, KOD and ESPR.

Is EDIT a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6968 seconds.